United StatesÚltimas notícias

Kyivstar Group (NASDAQ:KYIV) announced the acquisition of six solar power plants in Ukraine’s Lviv region for a total consideration of UAH 3.6 billion (approximately $80.8 million), accelerating the telecommunication firm’s vertical integration into sovereign power generation to mitigate localized infrastructure risks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) unveiled new clinical data expanding the medical profile of plozasiran, its approved RNA interference (RNAi) therapeutic, demonstrating that the drug can be administered to patients suffering from moderate-to-severe renal impairment or moderate hepatic impairment without necessitating a reduction in dose.

The AI data center boom is becoming an industrial arms race. CyrusOne CEO Eric Schwartz joined Bloomberg Open Interest to explain why the future of AI depends on power grids, skilled labor, and trillion-dollar infrastructure bets.

Wall Street's AI boom is spilling into credit markets. As hyperscalers' issue huge amounts of debt, banks are buying protection to manage exposure, while hedge funds sell that protection for what looks like easy money. But if the AI race starts producing winners and losers, this quiet CDS trade could become much riskier.

Eli Lilly is developing a groundbreaking one-time gene-editing treatment that could permanently lower bad cholesterol and reduce heart disease risk. Bloomberg's Madison Muller joins Open Interest to break down the science, the risks, and why Lilly is racing to expand beyond obesity drugs into its next major growth era.

Shares of Micron Technology (NASDAQ:MU) surged to an all-time intraday high following a dramatic price target increase from UBS, which argued that the artificial intelligence infrastructure buildout has permanently altered the financial predictability and valuation framework of the memory chip industry.

Ferrari's first fully electric car is already dividing fans. Critics say the $640K EV looks more like a Nissan Leaf or "a bar of soap" than a Ferrari, but the company may not care. Bloomberg's Craig Trudell joins Open Interest to explain why Ferrari only needs a handful of wealthy buyers to make the Luce a success, and how the brand could use the EV to unlock access to future supercars.

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports.

On this episode of Stock Movers: - AutoZone (AZO) shares fall after the retailer of automotive replacement parts posted comparable sales for the third quarter that fell short of Wall Street's expectations. - Ferrari (RACE IM) shares fell almost 8% after critics panned the look of its first fully electric vehicle, a setback for the Italian super-car maker's controversial push into EVs. - Eli Lilly (LLY) agreed to buy three vaccine developers for as much as $3.8 billion, marking the drugmaker's re-entry into the infectious disease space.

Space and satellite stocks are surging as SpaceX begins its IPO roadshow. Elon Musk's company filed last week for what stands to be the biggest initial public offering ever. On Friday, the company's Starship launched and successfully deployed mock satellites before returning to Earth safely. Bloomberg's Ed Ludlow reports.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) released updated Phase 1/2 clinical data for its experimental antibody-drug conjugate, CRB-701, demonstrating therapeutic activity in patients with pretreated, human papillomavirus (HPV)-associated solid tumors that express high levels of the Nectin-4 protein.

UBS raised its price target on Micron to a Street-high view of $1,625, up from $535. Mandeep Singh has more on "Bloomberg Open Interest."